drugset
drugset / Trial / NCT00041990

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

NCT00041990 ↗

Phase 2 Completed 40 enrolled Astex Pharmaceuticals, Inc. Eisai Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To determine the safety and efficacy of decitabine in patients with Philadelphia chromosome-positive chronic myelogenous leukemia accelerated phase that were previously treated with imatinib mesylate (STI 571) and became resistant/refractory or were found to be intolerant to the drug.

Timeline

Start
2002-07
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Decitabine Small molecule — —

Indications

chronic myeloid leukemia